

Royal Australian and New Zealand College of Psychiatrists  
the management of schizophrenia and related disorders

Australian and New Zealand Journal of Psychiatry

50, 410-472

DOI: [10.1177/0004867416641195](https://doi.org/10.1177/0004867416641195)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treating schizophrenia and supporting recovery: aligning clinician and patient goals. <i>Australasian Psychiatry</i> , 2016, 24, 329-330.	0.4	0
2	Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 242.	0.4	9
3	A year of guidelines: What have we learnt?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1121-1122.	1.3	0
4	Randomised controlled trial of a digitally assisted low intensity intervention to promote personal recovery in persisting psychosis: SMART-Therapy study protocol. <i>BMC Psychiatry</i> , 2016, 16, 312.	1.1	34
5	Commentary on Galletly et al. (2016), The Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1105-1106.	1.3	0
6	The treatment of schizophrenia: Can we raise the standard of care?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1128-1138.	1.3	30
7	NICE guidelines for schizophrenia: can art therapy be justified?. <i>Lancet Psychiatry</i> , 2016, 3, 1016-1017.	3.7	6
8	Outcomes following first-episode psychosis – Why we should intervene early in all ages, not only in youth. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1055-1063.	1.3	25
9	Why not rapid clozapine dose titration?. <i>Asian Journal of Psychiatry</i> , 2017, 26, 13.	0.9	0
10	Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. <i>BMJ Open</i> , 2017, 7, e013881.	0.8	92
11	Guilt, shame and expressed emotion in carers of people with long-term mental health difficulties: A systematic review. <i>Psychiatry Research</i> , 2017, 249, 139-151.	1.7	38
12	Premature death in schizophrenia: bridging the gap. <i>Lancet Psychiatry</i> , 2017, 4, 263-265.	3.7	20
13	Commentary on Galletly et al. (2016), The Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 288-289.	1.3	0
14	Targeting Zero: Implications for public psychiatric services. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 560-562.	1.3	4
15	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 235-248.	0.9	19
16	Can cognitive remediation improve subsequent response to low-intensity cognitive behaviour therapy for psychosis in people with schizophrenia?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 117-118.	1.3	2
17	Sexual dimorphism of the planum temporale in schizophrenia: A MRI study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1010-1019.	1.3	5
18	Treating schizophrenia during menopause. <i>Menopause</i> , 2017, 24, 582-588.	0.8	34

#	ARTICLE	IF	CITATIONS
19	Distress, Psychotic Symptom Exacerbation, and Relief in Reaction to Talking about Trauma in the Context of Beneficial Trauma Therapy: Perspectives from Young People with Post-Traumatic Stress Disorder and First Episode Psychosis. <i>Behavioural and Cognitive Psychotherapy</i> , 2017, 45, 561-576.	0.9	27
20	Caregiving roles: when will they be routinely recognized and supported?. <i>Journal of Mental Health</i> , 2017, 26, 95-97.	1.0	7
21	Responding to challenges for people with psychotic illness: Updated evidence from the Survey of High Impact Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 124-140.	1.3	81
22	The RANZCP guidelines for Schizophrenia: Why is our practice so far short of our recommendations, and what can we do about it?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 670-674.	1.3	7
23	Trauma, treatment and temperament: From troubling times to troubled thinking. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 655-657.	1.3	0
24	Embedding exercise interventions as routine mental health care: implementation strategies in residential, inpatient and community settings. <i>Australasian Psychiatry</i> , 2017, 25, 451-455.	0.4	61
25	Structural brain changes in schizophrenia at different stages of the illness: A selective review of longitudinal magnetic resonance imaging studies. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 500-508.	1.3	152
26	Royal Australian and New Zealand College of Psychiatrists expert consensus statement for the treatment, management and monitoring of the physical health of people with an enduring psychotic illness. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 322-337.	1.3	35
27	Raising the standard of care in the treatment of schizophrenia: Yes we can!. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 438-440.	1.3	4
28	Poor physical health in mental health: Finding a way forward. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 410-411.	1.3	1
29	Re: Can Cognitive Remediation improve subsequent response to low-intensity Cognitive Behaviour Therapy for Psychosis in people with schizophrenia?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 190-191.	1.3	1
30	Commentary on RANZCP clinical practice guidelines for the management of schizophrenia and related disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 289-290.	1.3	5
31	Long-term employment among people at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2017, 184, 26-31.	1.1	28
32	The importance of the physical health needs of people with psychotic disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 94-95.	1.3	8
33	Why not clozapine for the patient with schizophrenia at risk of suicide?. <i>Asian Journal of Psychiatry</i> , 2017, 26, 6-7.	0.9	1
34	The clinical utility of therapeutic drug monitoring for clozapine. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 295-296.	1.3	5
35	Identification of the delivery of cognitive behavioural therapy for psychosis (CBTp) using a cross-sectional sample from electronic health records and open-text information in a large UK-based mental health case register. <i>BMJ Open</i> , 2017, 7, e015297.	0.8	31
36	The imperative to screen for obstructive sleep apnoea in people with schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 737-738.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Enduring themes across journal issues. Australian and New Zealand Journal of Psychiatry, 2017, 51, 859-859.	1.3	0
38	Combination Antipsychotic Therapies. Journal of Clinical Psychopharmacology, 2017, 37, 595-599.	0.7	6
39	A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications. Canadian Journal of Cardiology, 2017, 33, 1577-1586.	0.8	16
40	Reducing the Risk of Cardiovascular Diseases in Non-selected Outpatients With Schizophrenia: A 30-Month Program Conducted in a Real-life Setting. Archives of Psychiatric Nursing, 2017, 31, 602-609.	0.7	11
41	Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology, 2017, 234, 3279-3297.	1.5	81
42	An appraisal of practice guidelines for smoking cessation in people with severe mental illness. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1106-1120.	1.3	5
43	Prolactin monitoring in schizophrenia should be indicated by symptomatology not time. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1152-1153.	1.3	0
44	The 2016 RANZCP Guidelines for the Management of Schizophrenia and Related Disorders – what’s next?. Australasian Psychiatry, 2017, 25, 600-602.	0.4	6
45	Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. Australasian Psychiatry, 2017, 25, 387-390.	0.4	4
46	A stitch in time: 3-monthly long-acting injectable paliperidone palmitate in schizophrenia. Therapeutic Advances in Psychopharmacology, 2017, 7, 231-233.	1.2	5
47	Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management. CNS Drugs, 2017, 31, 777-795.	2.7	37
48	Family Therapy for a Korean Son with Schizophrenia. Australian and New Zealand Journal of Family Therapy, 2017, 38, 529-539.	0.6	2
49	Men and women with psychosis and the impact of illness-duration on sex-differences: The second Australian national survey of psychosis. Psychiatry Research, 2017, 256, 130-143.	1.7	15
50	Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. Australasian Psychiatry, 2017, 25, 614-616.	0.4	13
51	Prevalence and correlates of suboptimal vitamin D status in people living with psychotic disorders: Data from the Australian Survey of High Impact Psychosis. Australian and New Zealand Journal of Psychiatry, 2017, 51, 921-929.	1.3	11
52	Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. British Journal of Psychiatry, 2017, 211, 175-181.	1.7	302
53	Ventricular volumes across stages of schizophrenia and other psychoses. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1041-1051.	1.3	17
54	Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points. BMC Psychiatry, 2017, 17, 139.	1.1	15

#	ARTICLE	IF	CITATIONS
55	Evaluating the effectiveness of a healthy lifestyle clinician in addressing the chronic disease risk behaviours of community mental health clients: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 276.	0.7	11
56	Reality of working in a community-based, recovery-oriented mental health rehabilitation unit: A pragmatic grounded theory analysis. <i>International Journal of Mental Health Nursing</i> , 2017, 26, 355-365.	2.1	26
57	Commentary on RANZCP clinical practice guidelines for the management of schizophrenia and related disorders – Section on pregnancy and schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 287-288.	1.3	2
58	How long will we sleep on obstructive sleep apnoea in schizophrenia?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 95-96.	1.3	3
59	Improving safety for women in psychiatry wards. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 192-194.	1.3	8
60	The Royal Australian and New Zealand College of Psychiatrists guidelines: Acute inpatient care for schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 191-192.	1.3	3
61	Improving safety for women in psychiatric wards. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 194-195.	1.3	1
62	Antineuronal antibody screening in early onset-cognitive decline. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 736-737.	1.3	0
63	Is it time to rethink treatment of early psychosis?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 291-292.	1.3	3
64	Good guidelines but should the emphasis be on implementation?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 15-17.	1.3	0
65	Something old and something blue – Something for everyone, me and you?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 757-758.	1.3	0
66	Psychotropic Medication and Substance Use during Pregnancy by Women with Severe Mental Illness. <i>Frontiers in Psychiatry</i> , 2017, 8, 28.	1.3	4
67	Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2174.	1.8	62
68	Cardiovascular disease in patients with schizophrenia. <i>Medical Journal of Australia</i> , 2017, 206, 91-95.	0.8	51
69	The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders. <i>Medical Journal of Australia</i> , 2017, 206, 501-505.	0.8	22
70	Participation in mental healthcare: a qualitative meta-synthesis. <i>International Journal of Mental Health Systems</i> , 2017, 11, 67.	1.1	39
71	Optimizing psychosocial interventions in first-episode psychosis: current perspectives and future directions. <i>Psychology Research and Behavior Management</i> , 2017, Volume 10, 119-128.	1.3	24
72	Psychopharmacological Treatment Patterns in Patients with Schizophrenia and Schizoaffective Disorder in Forensic Inpatient Settings. <i>Korean Journal of Legal Medicine</i> , 2017, 41, 115.	0.1	1

#	ARTICLE	IF	CITATIONS
73	Enabling choice, recovery and participation: evidence-based early intervention support for psychosocial disability in the National Disability Insurance Scheme. <i>Australasian Psychiatry</i> , 2018, 26, 578-585.	0.4	8
74	Taking action to reduce mental disorders: Clinical intervention and beyond. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 223-224.	1.3	0
75	Use of risk assessment instruments to predict violence in forensic psychiatric hospitals: a systematic review and meta-analysis. <i>European Psychiatry</i> , 2018, 52, 47-53.	0.1	79
76	Compliance of metabolic monitoring at rehabilitation facilities. <i>Australasian Psychiatry</i> , 2018, 26, 41-46.	0.4	3
77	Neurocognitive and Self-efficacy Benefits of Cognitive Remediation in Schizophrenia: A Randomized Controlled Trial. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 549-562.	1.2	30
78	Paliperidone palmitate three-month depot formulation: a helpful innovation with practical pitfalls. <i>Australasian Psychiatry</i> , 2018, 26, 206-209.	0.4	1
79	Addiction Vulnerability: Exploring Relationships Among Cigarette Smoking, Substance Misuse, and Early Psychosis. <i>Journal of Dual Diagnosis</i> , 2018, 14, 78-88.	0.7	4
80	Childhood Trauma Is Associated With Severity of Hallucinations and Delusions in Psychotic Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1111-1122.	2.3	198
81	Systematic review of interventions to increase the provision of care for chronic disease risk behaviours in mental health settings: review protocol. <i>Systematic Reviews</i> , 2018, 7, 67.	2.5	1
82	Severity of illness and adaptive functioning predict quality of care of children among parents with psychosis: A confirmatory factor analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 435-445.	1.3	24
83	Violent offending in schizophrenia spectrum disorders preceding and following diagnosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 782-792.	1.3	25
84	The Recovery Assessment Scale " Domains and Stages (RAS-DS): Sensitivity to change over time and convergent validity with level of unmet need. <i>Psychiatry Research</i> , 2018, 261, 560-564.	1.7	9
85	Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders. <i>Microbial Biotechnology</i> , 2018, 12, 928-934.	0.9	15
86	Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study. <i>Schizophrenia Bulletin</i> , 2018, 44, 93-100.	2.3	11
87	Using "WeChat"™ online social networking in a real-world needs analysis of family members of youths at clinical high risk of psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 375-382.	1.3	17
88	Randomised controlled trial of a healthy lifestyle intervention among smokers with psychotic disorders: Outcomes to 36 months. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 239-252.	1.3	27
89	Effectiveness of a treatment guideline for schizophrenia in adolescents: Lessons from a middle-income country. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 192-199.	1.3	2
90	Treating body, treating mind: The experiences of people with psychotic disorders and their general practitioners " Findings from the Australian National Survey of High Impact Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 561-572.	1.3	7

#	ARTICLE	IF	CITATIONS
91	Behavioural assessment unit improves outcomes for patients with complex psychosocial needs. <i>EMA - Emergency Medicine Australasia</i> , 2018, 30, 353-358.	0.5	21
92	Antipsychotic polypharmacy in older Australians. <i>International Psychogeriatrics</i> , 2018, 30, 539-546.	0.6	6
93	Saffron (adjunct) for people with schizophrenia who have antipsychotic-induced metabolic syndrome. <i>The Cochrane Library</i> , 0, , .	1.5	3
94	Reducing the Risk of Type 2 Diabetes in Nonselected Outpatients With Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2018, 24, 21-31.	0.3	7
95	Switch-associated adverse events: focus on olanzapine. <i>Australasian Psychiatry</i> , 2018, 26, 635-639.	0.4	4
96	A Randomized Controlled Trial on Mutual Support Group Intervention for Families of People With Recent-Onset Psychosis: A Four-Year Follow-Up. <i>Frontiers in Psychiatry</i> , 2018, 9, 710.	1.3	17
97	Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS): Rationale, Design, and Characteristics. <i>Frontiers in Psychiatry</i> , 2018, 9, 662.	1.3	2
98	Psychosocial Intervention for Patients with Schizophrenia. <i>Journal of Korean Neuropsychiatric Association</i> , 2018, 57, 235.	0.2	14
99	Informal Caregiving Relationships in Psychosis: Reviewing the Impact of Patient Violence on Caregivers. <i>Frontiers in Psychology</i> , 2018, 9, 1530.	1.1	17
100	Treating difficult-to-treat psychosis: Comments on Siskind et al. (2018). <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1215-1215.	1.3	1
101	Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1202-1212.	1.3	12
102	Diverse definitions of the early course of schizophrenia—a targeted literature review. <i>NPJ Schizophrenia</i> , 2018, 4, 21.	2.0	52
103	Development of a Strategic Tool for Shared Decision-Making in the Use of Antidepressants among Patients with Major Depressive Disorder: A Focus Group Study. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1402.	1.2	10
104	Improving the cardiometabolic health of people with psychosis: A protocol for a randomised controlled trial of the Physical Health Nurse Consultant service. <i>Contemporary Clinical Trials</i> , 2018, 73, 75-80.	0.8	5
105	Schizophrenia and Exercise. , 2018, , 65-82.		0
106	Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis. <i>CNS Drugs</i> , 2018, 32, 1011-1023.	2.7	19
107	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , 2018, 17, 149-160.	4.8	188
108	Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 289-299.	2.2	19

#	ARTICLE	IF	CITATIONS
109	A systematic scoping review of psychological therapies for psychosis within acute psychiatric in-patient settings. <i>British Journal of Psychiatry</i> , 2018, 213, 490-497.	1.7	31
110	Community pharmacists's attitudes and opinions towards supplying clozapine. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1116-1130.	1.0	4
111	Testing for antibodies to N-methyl-D-aspartate receptor and other neuronal cell surface antigens in patients with early psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 727-729.	1.3	17
112	The impact of intrinsic motivation on session attendance and reliable cognitive improvement in cognitive remediation in schizophrenia. <i>Schizophrenia Research</i> , 2018, 202, 354-360.	1.1	25
113	Screening for obstructive sleep apnoea in inpatients with schizophrenia: A feasibility study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 898-899.	1.3	1
114	Editorial: Family Interventions in Psychosis Change Outcomes in Early Intervention Settings – How Much Does the Evidence Support This?. <i>Frontiers in Psychology</i> , 2018, 9, 406.	1.1	6
115	Community-Based Psychosocial Treatment Has an Impact on Social Processing and Functional Outcome in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 247.	1.3	16
116	Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment. <i>Frontiers in Public Health</i> , 2018, 6, 166.	1.3	16
117	Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate. <i>Australasian Psychiatry</i> , 2018, 26, 628-634.	0.4	9
118	Implementing cognitive remediation and social cognitive interaction training into standard psychosis care. <i>BMC Health Services Research</i> , 2018, 18, 458.	0.9	16
119	The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. <i>BJPsych Open</i> , 2018, 4, 69-74.	0.3	48
120	Prescribed sedative and other psychotropic medication use among clients attending alcohol and other drug treatment. <i>Drug and Alcohol Review</i> , 2018, 37, 738-742.	1.1	8
121	Refining the psychiatric syndrome of anti-N-methyl-D-aspartate receptor encephalitis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 401-408.	2.2	87
122	A mental health home visit service partnership intervention on improving patients' satisfaction. <i>Archives of Psychiatric Nursing</i> , 2018, 32, 610-616.	0.7	5
123	Clozapine toxicity in a CYP2D6 poor metaboliser: Additive effects of haloperidol and valproate on clozapine metabolism. <i>Australasian Psychiatry</i> , 2018, 26, 608-611.	0.4	4
124	Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. <i>PLoS ONE</i> , 2018, 13, e0201371.	1.1	44
125	Metacognition – What did James H. Flavell really say and the implications for the conceptualization and design of metacognitive interventions. <i>Schizophrenia Research</i> , 2018, 201, 20-26.	1.1	119
126	Telephone-delivered psychosocial interventions targeting key health priorities in adults with a psychotic disorder: systematic review. <i>Psychological Medicine</i> , 2018, 48, 2637-2657.	2.7	18



#	ARTICLE	IF	CITATIONS
127	Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. <i>Angiology</i> , 2019, 70, 103-129.	0.8	20
128	Receipt and targeting of evidence-based psychosocial interventions for people living with psychoses: findings from the second Australian national survey of psychosis. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 613-629.	1.8	12
129	People who experience seclusion in adult mental health inpatient services: An examination of health of the nation outcome scales scores. <i>International Journal of Mental Health Nursing</i> , 2019, 28, 199-208.	2.1	14
130	Impact of <i>CYP1A2</i> genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 15-25.	2.2	21
131	Is it time to include people with intellectual disabilities in Royal Australian and New Zealand College of Psychiatrists' treatment guidelines?. <i>Australasian Psychiatry</i> , 2019, 27, 519-521.	0.4	2
132	Clinical Staging and Its Potential to Enhance Mental Health Care. , 2019, , 12-33.		5
133	Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1611-1620.	2.8	6
134	Therapeutic drug monitoring (TDM) during maintenance phase treatment at a community mental health centre. <i>Australasian Psychiatry</i> , 2019, 27, 637-640.	0.4	2
135	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics. <i>JAMA Psychiatry</i> , 2019, 76, 1052.	6.0	243
136	We snooze, they lose: where is the conversation about obstructive sleep apnoea in early psychosis?. <i>Australasian Psychiatry</i> , 2019, 27, 314-314.	0.4	2
137	Factors related to hospital utilisation for people living with schizophrenia: Examining Allen's Cognitive Level Scores, recommended supports and routinely collected variables. <i>Australian Occupational Therapy Journal</i> , 2019, 66, 591-602.	0.6	4
138	Aeromedical retrievals of people for mental health care and the low level of clinical support in rural and remote Australia. <i>Medical Journal of Australia</i> , 2019, 211, 351-356.	0.8	24
139	The case for improved care and provision of treatment for people with first-episode mania. <i>Lancet Psychiatry</i> , 2019, 6, 869-876.	3.7	46
140	Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 560-573.	1.0	32
141	Evaluating the effectiveness of brief cognitive behaviour therapy for distressing voices in routine clinical practice in an uncontrolled study. <i>Clinical Psychology and Psychotherapy</i> , 2019, 26, 734-742.	1.4	9
142	Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication. <i>Psychiatry Research</i> , 2019, 281, 112606.	1.7	16
143	Trial implementation of CIRCuiTS cognitive remediation therapy for people with schizophrenia in Orange, New South Wales. <i>Australian Journal of Rural Health</i> , 2019, 27, 463-468.	0.7	5
144	Acute psychosis and concurrent rhabdomyolysis unveiling diagnosis of hypothyroidism. <i>BMJ Case Reports</i> , 2019, 12, e231579.	0.2	11

#	ARTICLE	IF	CITATIONS
145	Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life?. <i>European Journal of Health Economics</i> , 2019, 20, 1425-1435.	1.4	12
146	Balancing body and mind: selecting the optimal antipsychotic. <i>Lancet, The</i> , 2019, 394, 900-902.	6.3	4
147	Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. <i>Asian Journal of Psychiatry</i> , 2019, 45, 74-80.	0.9	38
148	&lt;p&gt;A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2559-2569.	1.0	42
149	Well-informed but not aware: The P.A.C.T.Â® psychoeducation program for schizophrenia improves knowledge about, but not insight into, the illness. <i>Asian Journal of Psychiatry</i> , 2019, 46, 15-18.	0.9	11
150	Colorectal, cervical and prostate cancer screening in Australians with severe mental illness: Retrospective nation-wide cohort study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 550-558.	1.3	21
151	The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. <i>Psychopharmacology</i> , 2019, 236, 1931-1935.	1.5	20
152	Neural responses to criticism and praise vary with schizotypy and perceived emotional support. <i>International Journal of Psychophysiology</i> , 2019, 145, 109-118.	0.5	8
153	Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 209, 50-57.	1.1	27
154	Acute electroconvulsive therapy in the elderly with schizophrenia and schizoaffective disorder: A case series. <i>Asia-Pacific Psychiatry</i> , 2019, 11, e12361.	1.2	5
155	The clinical utility of structural neuroimaging in first-episode psychosis: A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 1093-1104.	1.3	21
156	Trajectories of antipsychotic use before and during pregnancy and associated maternal and birth characteristics. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 1208-1221.	1.3	8
157	EEG changes in patients on antipsychotic therapy: A systematic review. <i>Epilepsy and Behavior</i> , 2019, 95, 1-9.	0.9	28
158	Communication of treatment duration in schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 727-728.	1.3	1
159	Prescribing trends and safety of clozapine in an older persons mental health population. <i>International Psychogeriatrics</i> , 2019, 31, 1823-1829.	0.6	7
160	Paliperidone Long-Acting Injections in Huntingtonâ€™s Disease for Motor and Behavioural Disturbances. <i>Clinical Drug Investigation</i> , 2019, 39, 407-410.	1.1	5
161	Brain imaging in psychiatric disorders: target or screen?. <i>BJPsych Open</i> , 2019, 5, e4.	0.3	9
162	Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 609-623.	1.3	98

#	ARTICLE	IF	CITATIONS
163	Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome. Australian and New Zealand Journal of Psychiatry, 2019, 53, 509-527.	1.3	20
164	Acute electroconvulsive therapy in the elderly with schizophrenia and schizoaffective disorder: a literature review. Australasian Psychiatry, 2019, 27, 472-476.	0.4	5
165	Music Therapy as Treatment of Negative Symptoms for Adult Patients Diagnosed with Schizophrenia—Study Protocol for a Randomized, Controlled and Blinded Study. Medicines (Basel), 2019, 6, 107. DOI: 10.3390/med6010107	0.0	0
166	Medication-related issues associated with the documentation and administration of long-acting injectable antipsychotics. International Journal of Clinical Pharmacy, 2019, 41, 623-629.	1.0	3
167	Sociodemographic, environmental characteristics and comorbidities of older adults with schizophrenia who access community health service support: A national cross-sectional study. Australian and New Zealand Journal of Psychiatry, 2019, 53, 570-580.	1.3	5
168	A structured review of psychiatric rehabilitation for individuals living with severe mental illness within three regions of the Asia-Pacific: Implications for practice and policy. Asia-Pacific Psychiatry, 2019, 11, e12349.	1.2	16
169	Dietary intake of people with severe mental illness: systematic review and meta-analysis. British Journal of Psychiatry, 2019, 214, 251-259.	1.7	160
170	Management or missed opportunity? Mental health care planning in Australian general practice. Australian Journal of Primary Health, 2019, 25, 332.	0.4	7
171	Psychosocial interventions for people with both severe mental illness and substance misuse. The Cochrane Library, 2019, 2019, CD001088.	1.5	40
172	Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia. Korean Journal of Schizophrenia Research, 2019, 22, 21.	0.3	5
173	Maintenance treatment for patients with a first psychotic episode. Current Opinion in Psychiatry, 2019, 32, 147-156.	3.1	4
174	Eye movement desensitization and reprocessing (EMDR) therapy for posttraumatic stress disorder in adults with serious mental illness within forensic and rehabilitation services: a study protocol for a randomized controlled trial. Trials, 2019, 20, 642.	0.7	11
175	Federated multi-site longitudinal study of at-risk mental state for psychosis in Japan. Schizophrenia Research, 2019, 204, 343-352.	1.1	4
176	Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. Psychopharmacology, 2019, 236, 723-730.	1.5	6
177	Testing models of post-traumatic intrusions, trauma-related beliefs, hallucinations, and delusions in a first episode psychosis sample. British Journal of Clinical Psychology, 2019, 58, 154-172.	1.7	21
178	Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 183-198.	1.0	33
179	Are family warmth and positive remarks related to outcomes in psychosis? A systematic review. Psychological Medicine, 2019, 49, 1250-1265.	2.7	18
181	Does exercise improve sleep quality in individuals with mental illness? A systematic review and meta-analysis. Journal of Psychiatric Research, 2019, 109, 96-106.	1.5	83

#	ARTICLE	IF	CITATIONS
182	Talking about trauma in therapy: Perspectives from young people with post-traumatic stress symptoms and first episode psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 1236-1244.	0.9	19
183	ECT in schizophrenia: a review of the evidence. <i>Acta Neuropsychiatrica</i> , 2019, 31, 115-127.	1.0	55
184	Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: A multicentre study. <i>European Neuropsychopharmacology</i> , 2019, 29, 57-65.	0.3	14
185	Combination long-acting injectable (LAI) antipsychotic medication in adolescents with severe psychosis and aggression: a case series. <i>Australasian Psychiatry</i> , 2019, 27, 160-164.	0.4	10
186	Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis. <i>JAMA Psychiatry</i> , 2019, 76, 61.	6.0	33
187	Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first episode psychosis with low risk of self-harm or aggression. Study protocol and baseline characteristics of participants. <i>Microbial Biotechnology</i> , 2019, 13, 953-960.	0.9	19
188	Should people with psychosis be supported in choosing cognitive therapy as an alternative to antipsychotic medication: A commentary on current evidence. <i>Schizophrenia Research</i> , 2019, 203, 94-98.	1.1	11
189	Algorithm-based pharmacotherapy for first episode schizophrenia involuntarily hospitalized: A retrospective analysis of real-world practice. <i>Microbial Biotechnology</i> , 2019, 13, 39-46.	0.9	9
190	The extent of antipsychotic use in Australian residential aged care facilities and interventions shown to be effective in reducing antipsychotic use: A literature review. <i>Dementia</i> , 2020, 19, 1189-1202.	1.0	18
191	Self-reported physical activity levels of the 2017 Royal Australian and New Zealand College of Psychiatrists (RANZCP) conference delegates and their exercise referral practices. <i>Journal of Mental Health</i> , 2020, 29, 565-572.	1.0	12
192	Outcomes and change processes of an established family education program for carers of adults diagnosed with a serious mental health condition. <i>Psychological Medicine</i> , 2020, 50, 1099-1109.	2.7	4
193	Predictors and moderators of burden of care and emotional distress in first-episode psychosis caregivers: results from the GET UP pragmatic cluster randomised controlled trial. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e27.	1.8	2
194	Serum and CSF Anti-NMDAR Antibody Testing in Psychiatry. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 154-160.	0.9	16
195	Cannabis use and psychosis: a review of reviews. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 403-412.	1.8	123
196	Screening for obstructive sleep apnoea in an early psychosis cohort: a pilot study. <i>Australasian Psychiatry</i> , 2020, 28, 180-185.	0.4	2
197	Pathways to care, DUP, and types of interventions over 5 years following psychosis onset: findings from a naturalistic study conducted in routine generalist mental health services. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 175-186.	1.6	4
198	Assessing Cognition and Social Cognition in Schizophrenia & Related Disorders. , 2020, , 177-206.		1
199	Trauma Therapies in Psychosis. , 2020, , 447-463.		8

#	ARTICLE	IF	CITATIONS
200	A Brief Guide to Medications for Psychosis. , 2020, , 537-560.		1
201	Getting in Early: Early Intervention Services for Psychosis. , 2020, , 561-588.		0
202	What Is Psychosis?. , 2020, , 3-36.		0
203	The Prodrome of Psychotic Disorders. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 57-69.	1.0	9
204	Measurement and Management of QT Interval Prolongation for General Physicians. <i>Journal of General Internal Medicine</i> , 2020, 35, 865-873.	1.3	19
205	Cognitive behavioural family intervention for people diagnosed with severe mental illness and their families: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2020, 27, 128-139.	1.2	16
206	Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm. <i>CNS Drugs</i> , 2020, 34, 117-126.	2.7	10
207	Trial Implementation of CIRCuITS Cognitive Remediation Therapy for People with Schizophrenia in Rural Australia: Therapists Experiences. <i>Journal of Psychosocial Rehabilitation and Mental Health</i> , 2020, 7, 5-14.	0.4	1
208	The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples. <i>Schizophrenia Research</i> , 2020, 225, 4-14.	1.1	15
209	Pilot randomised controlled trial of a brief coping-focused intervention for hearing voices blended with smartphone-based ecological momentary assessment and intervention (SAVVy): Feasibility, acceptability and preliminary clinical outcomes. <i>Schizophrenia Research</i> , 2020, 216, 479-487.	1.1	40
210	When to consider electroconvulsive therapy (ECT). <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 304-315.	2.2	107
211	Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2020, 215, 8-16.	1.1	49
212	The Wellness Clinic: A retrospective Quasi-experimental, longitudinal study of physical health support in an Australian mental health service setting. <i>International Journal of Mental Health Nursing</i> , 2020, 29, 1112-1119.	2.1	1
213	Health Professionals as Mothers of Adult Children With Schizophrenia. <i>Qualitative Health Research</i> , 2020, 30, 1807-1820.	1.0	2
214	The psychosis analysis in real-world on a cohort of large-scale patients with schizophrenia. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 132.	1.5	4
215	Sleep-disordered breathing in severe mental illness: clinical evaluation of oximetry diagnosis and management limitations. <i>Sleep and Breathing</i> , 2021, 25, 1433-1440.	0.9	0
216	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. <i>Schizophrenia Research</i> , 2021, 230, 87-94.	1.1	2
217	An integrative collaborative care model for people with mental illness and physical comorbidities. <i>International Journal of Mental Health Systems</i> , 2020, 14, 83.	1.1	33

#	ARTICLE	IF	CITATIONS
218	Physical health assessment and cardiometabolic monitoring practices across three adult mental health inpatient units – a retrospective cohort study. <i>International Journal of Mental Health Nursing</i> , 2020, 29, 1144-1156.	2.1	1
219	Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone). <i>Microbial Biotechnology</i> , 2021, 15, 787-793.	0.9	10
220	Post-traumatic growth: Health professionals as mothers of adult children with schizophrenia. <i>Health Care for Women International</i> , 2020, 41, 916-927.	0.6	1
221	Replacing Unhealthy EE with Healthy EE in Schizophrenia: Towards a Public Health Model of Cognitive Rehabilitation for Low-Resource Settings. <i>Journal of Psychosocial Rehabilitation and Mental Health</i> , 2020, 7, 107-110.	0.4	0
222	Quetiapine withdrawal: A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 772-783.	1.3	7
223	Implementation of guidelines on family involvement for persons with psychotic disorders in community mental health centres (IFIP): protocol for a cluster randomised controlled trial. <i>BMC Health Services Research</i> , 2020, 20, 934.	0.9	10
224	Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. <i>Frontiers in Public Health</i> , 2020, 8, 391.	1.3	1
225	Concurrent Disorder Management Guidelines. Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2406.	1.0	30
226	Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues. <i>Drugs</i> , 2020, 80, 1635-1647.	4.9	5
227	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093790.	1.2	6
228	Mental health recovery and physical health outcomes in psychotic illness: Longitudinal data from the Western Australian survey of high impact psychosis catchments. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 55, 000486742095426.	1.3	13
229	Staging of depressive disorders: Relevance of resistance to treatment and residual symptoms. <i>Journal of Psychiatric Research</i> , 2020, 129, 234-240.	1.5	3
230	Schizotypy and help-seeking for anxiety. <i>Microbial Biotechnology</i> , 2020, 15, 1433-1436.	0.9	2
231	Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 1584-1594.	0.9	2
232	Clozapine in the management of persistent destructive behaviour in a 17-year-old boy with intellectual disability. <i>BMJ Case Reports</i> , 2020, 13, e235346.	0.2	2
233	Has improved treatment contributed to the declining rate of transition to psychosis in ultra-high-risk cohorts?. <i>Schizophrenia Research</i> , 2020, , .	1.1	12
234	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia – Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. <i>Schizophrenia Bulletin</i> , 2020, 46, 1459-1470.	2.3	58
235	An economic evaluation of a specialist preventive care clinician in a community mental health service: a randomised controlled trial. <i>BMC Health Services Research</i> , 2020, 20, 405.	0.9	2

#	ARTICLE	IF	CITATIONS
236	The effectiveness of interventions to increase preventive care provision for chronic disease risk behaviours in mental health settings: A systematic review and meta-analysis. Preventive Medicine Reports, 2020, 19, 101108.	0.8	9
237	High-dose antipsychotic therapy and reflective prescribing: development of an online tool for rapid, easy calculation of antipsychotic total daily dose. Australasian Psychiatry, 2020, 28, 410-413.	0.4	3
238	Neuroanatomical Features That Predict Response to Electroconvulsive Therapy Combined With Antipsychotics in Schizophrenia: A Magnetic Resonance Imaging Study Using Radiomics Strategy. Frontiers in Psychiatry, 2020, 11, 456.	1.3	10
239	Gastroenteritis exposure and the risk of schizophrenia onset: A systematic review and meta-analysis. Journal of Psychosomatic Research, 2020, 134, 110136.	1.2	1
240	Is higher psychotropic medication burden associated with involuntary treatment under the Mental Health Act? A four-year Australian cohort study. BMC Psychiatry, 2020, 20, 294.	1.1	7
241	Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. International Clinical Psychopharmacology, 2020, 35, 221-228.	0.9	15
242	Implementation and Outcomes of a Clozapine-Associated Myocarditis Screening Program in a Region of South Australia—Lessons Learned. Journal of Clinical Psychopharmacology, 2020, 40, 250-258.	0.7	14
243	Community-care unit model of residential mental health rehabilitation services in Queensland, Australia: predicting outcomes of consumers 1-year post discharge. Epidemiology and Psychiatric Sciences, 2020, 29, e109.	1.8	10
245	Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. Journal of Affective Disorders, 2020, 272, 508-520.	2.0	18
246	Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs, 2020, 34, 473-507.	2.7	38
247	A Feasibility Study of the Translation of Cognitive Behaviour Therapy for Psychosis into an Australian Adult Mental Health Clinical Setting. Behaviour Change, 2020, 37, 22-32.	0.6	2
248	Reducing barriers to the diagnosis of obstructive sleep apnoea in patients with severe mental illness. Australian and New Zealand Journal of Psychiatry, 2020, 54, 847-847.	1.3	0
249	Psychosocial interventions in schizophrenia: Focus on guidelines. International Journal of Social Psychiatry, 2020, 66, 735-747.	1.6	24
250	The physical health Wellness Clinic model of care for patients with mental health issues who are "hard to engage". Australasian Psychiatry, 2020, 28, 303-306.	0.4	2
251	Understanding the tests that we order: screening for anti-NMDA receptor encephalitis in first episode psychosis. Australasian Psychiatry, 2020, 28, 199-201.	0.4	3
252	Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin Open, 2020, 1, .	0.9	19
253	Risk of schizophrenia in relatives of individuals affected by schizophrenia: A meta-analysis. Psychiatry Research, 2020, 286, 112852.	1.7	7
254	Pharmacological intervention for people at risk of psychotic disorder. , 2020, , 371-381.		1

#	ARTICLE	IF	CITATIONS
255	Is cognitive behavioural therapy effective for individuals experiencing thought disorder?. Psychiatry Research, 2020, 285, 112806.	1.7	2
256	Screening for anti-NMDAR encephalitis in psychiatry. Journal of Psychiatric Research, 2020, 125, 28-32.	1.5	12
257	A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. Schizophrenia Research, 2020, 220, 92-97.	1.1	2
258	The role of key workers in improving physical health in first episode psychosis: A scoping review. Microbial Biotechnology, 2021, 15, 16-33.	0.9	3
259	Trauma and the content of hallucinations and post-traumatic intrusions in first episode psychosis. Psychology and Psychotherapy: Theory, Research and Practice, 2021, 94, 223-241.	1.3	24
260	Recommendations for the medical workup of first episode psychosis, including specific relevance to Indigenous Australians: A narrative review. Microbial Biotechnology, 2021, 15, 423-438.	0.9	1
261	Improving treatments for psychotic disorders: beyond cognitive behaviour therapy for psychosis. Psychosis, 2021, 13, 78-84.	0.4	14
262	Early intervention for risk syndromes: What are the real risks?. Schizophrenia Research, 2021, 227, 4-9.	1.1	16
263	When should we image our patients? Appropriate use of imaging in inpatient psychiatry. Australasian Psychiatry, 2021, 29, 286-288.	0.4	0
264	Antipsychotic choice: understanding shared decision-making among doctors and patients. Journal of Mental Health, 2021, 30, 66-73.	1.0	6
265	Placing rehabilitation at the core of assertive community treatment. Australasian Psychiatry, 2021, 29, 47-51.	0.4	3
266	A cross sectional study of psychotropic medicine use in Australia in 2018: A focus on polypharmacy. British Journal of Clinical Pharmacology, 2021, 87, 1369-1377.	1.1	12
267	Schizophrenia Psychosis in Women. Women, 2021, 1, 1-15.	0.5	9
268	Scoping Review of Family Interventions That Support the Physical Health of Caregivers. Research on Social Work Practice, 2021, 31, 234-243.	1.1	1
269	“I don’t think that everybody should be involved” What informs experiences of shared decision-making in supporting people living with schizophrenia spectrum disorders?. Patient Education and Counseling, 2021, 104, 1583-1590.	1.0	15
270	Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018 - A pharmacoepidemiology study. Research in Social and Administrative Pharmacy, 2021, 17, 1159-1165.	1.5	3
271	Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?. Expert Opinion on Pharmacotherapy, 2021, 22, 635-646.	0.9	6
272	Exploring the Health Status of People with First-Episode Psychosis Enrolled in the Early Intervention in Psychosis Program. Issues in Mental Health Nursing, 2021, 42, 57-64.	0.6	0



#	ARTICLE	IF	CITATIONS
273	Pharmacological management of comorbid obsessive-compulsive disorder and chronic non-affective psychosis. <i>BJ Psych Advances</i> , 2021, 27, 230-242.	0.5	0
274	Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. <i>Journal of Neurology</i> , 2021, 268, 1222-1246.	1.8	120
275	Working-memory impairment in schizophrenia and schizotypal personality disorder. , 2021, , 19-48.		1
276	Weitere wissenschaftlich fundierte Psychotherapiemethoden und -verfahren. , 2021, , 577-623.		0
277	Case Report: Successful Implementation of Integrative Cognitive Remediation for Early Psychosis. <i>Frontiers in Psychiatry</i> , 2020, 11, 624091.	1.3	1
278	Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e040387.	0.8	17
279	Case studies of the treatment of schizophrenia patients. , 2021, , 141-153.		0
280	Psychosocial rehabilitation interventions in the treatment of schizophrenia and bipolar disorder. <i>Noropsikiyatri Arsivi</i> , 2021, 58, S77-S82.	0.2	7
281	Voltage-gated potassium channel blanket testing in first-episode psychosis: Diagnostic nihilism?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 817-823.	1.3	2
282	Factors associated with laxative use in schizophrenia patients treated with second-generation antipsychotics. <i>European Neuropsychopharmacology</i> , 2021, 43, 139-146.	0.3	7
283	The coexistence of pituitary macroadenoma and schizophrenia – practical therapeutic implications based on the case report and the literature review. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2021, 36, 335-346.	0.1	0
284	Menstrual Dysfunction in Women With Schizophrenia During Risperidone Maintenance Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 135-139.	0.7	2
285	Use of the ADAPTE method to develop a clinical guideline for the improvement of psychoses and schizophrenia care: Example of involvement and participation of patients and family caregivers. <i>Health Expectations</i> , 2021, 24, 516-524.	1.1	3
286	A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 453-469.	1.0	5
287	A systematic review of clozapine's effectiveness for primary psychotic and bipolar disorders in older adults. <i>International Psychogeriatrics</i> , 2022, 34, 875-887.	0.6	7
288	Prospective Long-Term Cohort Study of Subjects With First-Episode Psychosis Examining Eight Major Outcome Domains and Their Predictors: Study Protocol. <i>Frontiers in Psychiatry</i> , 2021, 12, 643112.	1.3	12
289	Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia. <i>Behavioural Brain Research</i> , 2021, 402, 113099.	1.2	7
290	Antipsychotic Medications: Enhancing Use to Improve Outcomes. <i>Schizophrenia Bulletin</i> , 2021, 47, 1201-1204.	2.3	2

#	ARTICLE	IF	CITATIONS
291	Network Analysis of Symptom Comorbidity in Schizophrenia: Relationship to Illness Course and Brain White Matter Microstructure. <i>Schizophrenia Bulletin</i> , 2021, 47, 1156-1167.	2.3	10
292	Demonstration of automated non-adherence and service disengagement risk monitoring with active follow-up for severe mental illness. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 976-982.	1.3	7
293	Cardiovascular Disease and Mental Health in Men. , 2021, , 222-231.		0
294	Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study. <i>CNS Drugs</i> , 2021, 35, 655-665.	2.7	14
295	Medication strategies in first episode psychosis patients: A survey among psychiatrists. <i>Microbial Biotechnology</i> , 2022, 16, 139-146.	0.9	6
296	Antipsychotics and neutropenia: An update. <i>Annals of Psychiatry and Treatment</i> , 2021, , 023-027.	1.3	0
298	Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10. <i>International Clinical Psychopharmacology</i> , 2021, 36, 181-187.	0.9	5
299	Applicability of somatic monitoring instructions in clinical practice guidelines on antipsychotic drug use. <i>BMC Psychiatry</i> , 2021, 21, 189.	1.1	6
300	Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study. <i>Psychological Medicine</i> , 2023, 53, 181-188.	2.7	6
301	A qualitative exploration of factors contributing to non-guideline adherent antipsychotic polypharmacy. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 2457-2467.	1.5	3
302	Toward a Gender-Sensitive Approach of Psychiatric Rehabilitation in Autism Spectrum Disorder (ASD): A Systematic Review of Women Needs in the Domains of Romantic Relationships and Reproductive Health. <i>Frontiers in Psychiatry</i> , 2021, 12, 630029.	1.3	6
303	Anesthesia Considerations for Cataract Surgery in Patients with Schizophrenia: A Narrative Review. <i>Anesthesiology and Pain Medicine</i> , 2021, 11, e113750.	0.5	6
304	Characteristics of people on long-acting injectable antipsychotics in Australia: Data from the 2010 National Survey of High Impact Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 958-975.	1.3	4
305	Quels outils thérapeutiques en faveur du rétablissement dans la schizophrénie?. <i>Annales Medico-Psychologiques</i> , 2021, 179, 363-369.	0.2	0
306	EFFECT OF APPLYING "ACCEPTANCE AND COMMITMENT THERAPY" ON AUDITORY HALLUCINATIONS AMONG PATIENTS WITH SCHIZOPHRENIA. <i>Archives of Psychiatric Nursing</i> , 2021, 35, 141-152.	0.7	7
307	Continuation of Treatment With Clozapine After an Episode of Neutropenia. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 320-322.	0.7	2
308	Current and emerging long-acting antipsychotics for the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 771-790.	1.0	19
309	Ageing with psychosis " Fifty and beyond. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 39-49.	1.3	3

#	ARTICLE	IF	CITATIONS
310	Electroconvulsive Therapy in Children and Adolescents. <i>Journal of ECT</i> , 2021, 37, 158-170.	0.3	18
311	TPN672: A Novel Serotonin-Dopamine Receptor Modulator for the Treatment of Schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 20-30.	1.3	3
312	Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. <i>American Journal of Psychiatry</i> , 2021, 178, 424-436.	4.0	54
313	Approche psychologique des hallucinations et de l'expérience d'entente de voix: prises en charge psychologiques fondées sur les preuves (partie II). <i>Annales Medico-Psychologiques</i> , 2021, 179, 417-424.	0.2	1
314	Reducing metabolic syndrome in Australian patients: Metabolic Management During Antipsychotic Prescribing (MMAP) programme. <i>Australasian Psychiatry</i> , 2021, , 103985622110107.	0.4	0
315	Pre-empt aggression in prison and treat precipitating conditions. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 242-248.	0.3	0
316	Family involvement practices for persons with psychotic disorders in community mental health centres – a cross-sectional fidelity-based study. <i>BMC Psychiatry</i> , 2021, 21, 285.	1.1	16
317	Anti-NMDAR encephalitis for psychiatrists: the essentials. <i>BJPsych Bulletin</i> , 2022, 46, 235-241.	0.7	5
318	Augmentation of Antipsychotic Medications with Low-Dose Clozapine in Treatment-Resistant Schizophrenia – Case Reports and Discussion. <i>Case Reports in Psychiatry</i> , 2021, 2021, 1-5.	0.2	2
319	A practical toolkit to support Australian mental health clinicians to manage Metabolic Syndrome: A pilot study. <i>International Journal of Mental Health Nursing</i> , 2021, 30, 1417-1425.	2.1	2
320	Systematic Review of the Neural Effect of Electroconvulsive Therapy in Patients with Schizophrenia: Hippocampus and Insula as the Key Regions of Modulation. <i>Psychiatry Investigation</i> , 2021, 18, 486-499.	0.7	12
321	Antipsychotic-induced supersensitivity – A reappraisal. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 437-444.	1.3	3
322	Immediate and delayed effects of climatic factors on hospital admissions for schizophrenia in Queensland Australia: A time series analysis. <i>Environmental Research</i> , 2021, 197, 111003.	3.7	10
323	A systematic review of maternal and infant outcomes after clozapine continuation in pregnancy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 178-182.	1.2	4
324	Treating schizophrenia: Should we emphasise ‘first do no harm’?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, , 000486742110256.	1.3	0
325	Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN). <i>CNS Drugs</i> , 2021, 35, 893-905.	2.7	11
326	A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7239.	1.2	7
327	Relational Recovery for Mental Health Carers and Family: Relationships, Complexity and Possibilities. <i>British Journal of Social Work</i> , 2022, 52, 1325-1340.	0.9	6

#	ARTICLE	IF	CITATIONS
328	The Physical Health and Activity of Patients under Forensic Psychiatric Care: A Scoping Review. <i>International Journal of Forensic Mental Health</i> , 2022, 21, 194-209.	0.6	4
329	Physical activity and sedentary behaviour counselling: Attitudes and practices of mental health professionals. <i>PLoS ONE</i> , 2021, 16, e0254684.	1.1	3
330	Prescriptive practice of antipsychotics in 2013-2018 in schizophrenia based on data from the National Health Fund. <i>Psychiatria Polska</i> , 2021, , 1-16.	0.2	0
331	High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?. <i>Journal of Psychopharmacology</i> , 2021, 35, 1030-1036.	2.0	6
332	Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 146.	0.6	7
333	Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 434-448.	0.9	7
334	The effectiveness of metacognitive training on impairments in social cognition in patients with schizophrenia: mental health nursing practice in a community mental health center. <i>Nordic Journal of Psychiatry</i> , 2022, 76, 295-306.	0.7	1
335	Factors predicting high-dose and combined antipsychotic prescribing in New Zealand. <i>Psychiatry Research</i> , 2021, 302, 113996.	1.7	2
336	Rates of homicide and homicide associated with severe mental illness in NSW between 1993 and 2016. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 836-843.	1.3	4
337	Risk factors for early-phase clozapine discontinuation: A nested case-control study. <i>Asian Journal of Psychiatry</i> , 2021, 62, 102745.	0.9	1
338	Testing the Efficacy of Family Health-Model of REBT on Family Values and Quality of Family Life Among Parents of Children with Visual Impairment. <i>Journal of Rational - Emotive and Cognitive - Behavior Therapy</i> , 2022, 40, 252-277.	1.0	11
339	Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110275.	2.5	3
340	Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 583-590.	1.8	5
341	Excess mortality from cancer in people with mental illnessâ€”Out of sight and out of mind. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 315-317.	2.2	2
342	Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 591-602.	1.8	9
343	Improving Practices of Mental Health Professionals in Recommending More Physical Activity and Less Sedentary Behaviour to Their Clients: An Intervention Trial. <i>Issues in Mental Health Nursing</i> , 2022, 43, 258-264.	0.6	1
344	The Mark Sheldon Remote Mental Health Team: an evaluation of patient demographics, diagnoses and clinical management in very remote Central Australia. <i>Australasian Psychiatry</i> , 2022, 30, 79-83.	0.4	0
345	Insight and the number of completed modules predict a reduction of positive symptoms in an Internet-based intervention for people with psychosis. <i>Psychiatry Research</i> , 2021, 306, 114223.	1.7	5

#	ARTICLE	IF	CITATIONS
346	Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2021, 236, 142-155.	1.1	18
347	Menopause in women with schizophrenia, schizoaffective disorder and bipolar disorder. <i>Maturitas</i> , 2021, 152, 57-62.	1.0	12
348	L'impact de l'amélioration de la qualité de vie chez les patients atteints d'une schizophrénie fractaire ayant suivi la thérapie assistée par la réalité virtuelle: une analyse de contenu. <i>Sante Mentale Au Quebec</i> , 0, 46, 157-174.	0.1	1
349	Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. <i>Pharmacopsychiatry</i> , 2021, 54, 60-67.	1.7	10
350	Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study. <i>Human Psychopharmacology</i> , 2021, 36, e2777.	0.7	5
351	It's the one thing they have left: smoking, smoking cessation and mental health. , 2021, , 248-272.		1
352	Physical activity and severe mental illness. , 0, , 385-408.		3
353	Schizophrenia in Women. , 2020, , 49-58.		1
354	Antipsychotic Polypharmacy and High-Dose Antipsychotics in Involuntary Patients: a Seven-Year Audit of Discharge Prescriptions in an Acute Care Unit. <i>Psychiatric Quarterly</i> , 2021, 92, 1-14.	1.1	4
355	Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem. <i>Psychological Medicine</i> , 2020, 50, 2673-2681.	2.7	25
356	Understanding the lived experience of cognitive remediation in schizophrenia: A qualitative comparison with an active control.. <i>Psychiatric Rehabilitation Journal</i> , 2018, 41, 302-311.	0.8	14
357	Antipsychotic Polypharmacy. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 375-385.	0.4	5
358	Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis). <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 696-706.	1.3	24
359	Current inpatient prescription practices for the treatment of schizophrenia in public hospitals of Minas Gerais, Brazil. <i>Revista Brasileira De Psiquiatria</i> , 2017, 39, 190-192.	0.9	2
360	Stopping and switching antipsychotic drugs. <i>Australian Prescriber</i> , 2019, 42, 152.	0.5	38
361	Key Worker-Mediated Enhancement of Physical Health in First Episode Psychosis: Protocol For a Feasibility Study in Primary Care. <i>JMIR Research Protocols</i> , 2019, 8, e13115.	0.5	5
362	Developing a Hypothetical Implementation Framework of Expectations for Monitoring Early Signs of Psychosis Relapse Using a Mobile App: Qualitative Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e14366.	2.1	33
363	Digital Technology for Caregivers of People With Psychosis: Systematic Review. <i>JMIR Mental Health</i> , 2018, 5, e55.	1.7	16

#	ARTICLE	IF	CITATIONS
364	Metacognitive and cognitive-behavioral interventions for psychosis: new developments. Dialogues in Clinical Neuroscience, 2019, 21, 309-317.	1.8	50
365	STUDY ON TOLERABILITY AND EFFICACY OF PALIPERIDONE PALMITATE, OLANZAPINE PAMOATE AND RISPERIDONE LONG ACTING INJECTION IN A ROMANIAN SAMPLE OF PATIENTS WITH SCHIZOPHRENIA. Farmacia, 2020, 68, 242-249.	0.1	2
366	Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States. Journal of Clinical Psychiatry, 2020, 82, .	1.1	10
367	Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms. Clinical Psychopharmacology and Neuroscience, 2020, 18, 386-394.	0.9	19
368	Antipsychotic utilisation and persistence in Australia: A nationwide 5-year study. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1155-1163.	1.3	6
369	Mental health service engagement with family and carers: what practices are fundamental?. BMC Health Services Research, 2021, 21, 1073.	0.9	14
370	New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Medical Journal of Australia, 2021, 215, S3-S32.	0.8	34
371	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs, 2021, 35, 1189-1205.	2.7	32
372	Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study. Psychiatry Investigation, 2021, 18, 968-976.	0.7	0
373	Exploring Discharge Outcomes and Readmission Rates of Mothers Admitted to a Psychiatric Mother and Baby Unit. Psychiatric Quarterly, 2021, , 1.	1.1	3
374	Clinical Characteristics of Patients with Schizophrenia Maintained without Antipsychotics: A Cross-sectional Survey of a Case Series. Clinical Psychopharmacology and Neuroscience, 2021, 19, 773-779.	0.9	0
375	Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2021, 19, 600-609.	0.9	6
377	Psychosis: Schizophrenia and Related Disorders. , 2018, , 335-372.		0
378	A Survey Towards Holistic Management of Schizophrenia. Psychology Research (Libertyville, Ill ), 2018, 8, .	0.0	0
379	Comment d'écouter le premier épisode psychotique?. , 2019, , 37-47.		0
380	Comment aider les proches?. , 2019, , 155-164.		1
381	Attenuated Psychosis Syndromes Among Australian Youth and Young Adults: Early Identification and Intervention. , 2019, , 67-84.		0
383	Quelle modalité de traitement médicamenteux?. , 2019, , 103-114.		0

#	ARTICLE	IF	CITATIONS
384	Behandlung unter besonderen Bedingungen (Modul 4c). , 2019, , 181-254.		0
385	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
386	Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a). , 2019, , 51-137.		0
387	Klassifikation, Diagnostik und Differenzialdiagnostik (Modul 2). , 2019, , 13-36.		0
388	Do adjunctive art therapies reduce symptomatology in schizophrenia? A meta-analysis. World Journal of Psychiatry, 2019, 9, 107-120.	1.3	13
389	Profil Penggunaan Obat Kombinasi Risperidone-Clozapine dan Risperidone dengan Antipsikotik Lain pada Pasien Gangguan Mental Psikotik di Rumah Sakit Jiwa Grhasia Yogyakarta. Jurnal Surya Medika, 2020, 5, 131-138.	0.0	0
390	Keyworker mediated enhancement of physical health in patients with first episode psychosis: A feasibility/acceptability study. Microbial Biotechnology, 2021, , .	0.9	2
391	The <sc>MACâ€P</sc> program: A pilot study of a mindfulness and compassion program for youth with psychotic experiences. Microbial Biotechnology, 2021, 15, 1326-1334.	0.9	6
392	Appraisal of physical health guidelines for severe mental illness. Australian Health Review, 2020, 44, 904.	0.5	2
393	Antipsychotic Use in Community Mental Health Service. Open Journal of Psychiatry, 2020, 10, 45-52.	0.2	0
394	Prescription patterns of antipsychotics in the management of first episode psychosis at three psychiatric hospitals in Khartoum, 2018: A descriptive cross-sectional study. Journal of Family Medicine and Primary Care, 2020, 9, 402.	0.3	0
395	Neuropsychopharmacotherapy: Guidelines. , 2020, , 1-31.		0
396	Quality prescribing in early psychosis: key pharmacotherapy principles. Australasian Psychiatry, 2021, , 103985622110546.	0.4	2
397	Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. Psychopharmacology Bulletin, 2018, 48, 25-61.	0.0	9
398	Brain Imaging in New Onset Psychiatric Presentations. Innovations in Clinical Neuroscience, 2019, 16, 21-26.	0.1	2
399	Vocational Interventions to Improve Employment Participation of People with Psychosocial Disability, Autism and/or Intellectual Disability: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 12083.	1.2	10
400	Trends in Research on Art Therapy Indexed in the Web of Science: A Bibliometric Analysis. Frontiers in Psychology, 2021, 12, 752026.	1.1	5
402	The Quality of Internet Websites for People Experiencing Psychosis: Pilot Expert Assessment. JMIR Formative Research, 2022, 6, e28135.	0.7	3

#	ARTICLE	IF	CITATIONS
403	Factors influencing medication adherence among patients with severe mental disorders from the perspective of mental health professionals. <i>BMC Psychiatry</i> , 2022, 22, 22.	1.1	14
404	Demographic and clinical characteristics of patients who recommence clozapine following therapy interruptions. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 293-300.	2.2	3
405	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 201-219.	1.0	3
406	Antipsychotic prescribing patterns in Australia: a retrospective analysis. <i>BMC Psychiatry</i> , 2022, 22, 110.	1.1	7
407	From evidence to realities: psychosocial intervention provision in Australian routine community mental health practice. <i>Psychosis</i> , 0, , 1-13.	0.4	0
408	Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 469-480.	2.2	11
409	Fear of relapse in schizophrenia: a mixed-methods systematic review. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2022, 57, 1305-1318.	1.6	5
410	The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 784366.	1.3	4
412	Need for Psychiatric Rehabilitation Training for Mental Health Professionals. <i>Journal of Psychosocial Rehabilitation and Mental Health</i> , 0, , 1.	0.4	1
413	Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. <i>NPJ Schizophrenia</i> , 2022, 8, 5.	2.0	48
414	Quetiapine-associated thrombocytopenic purpura in a young man with a first episode schizophrenia. <i>L'Encephale</i> , 2023, 49, 100-102.	0.3	2
415	Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first-episode schizophrenia: A Nationwide, Health Insurance Data-based Study. <i>Psychiatry and Clinical Neurosciences</i> , 2022, , .	1.0	0
416	Trauma and psychosis: a qualitative study exploring the perspectives of people with psychosis on the influence of traumatic experiences on psychotic symptoms and quality of life. <i>BMC Psychiatry</i> , 2022, 22, 213.	1.1	8
417	Healthcare costs and resource use associated with negative symptoms of schizophrenia: A systematic literature review. <i>Schizophrenia Research</i> , 2022, 241, 251-259.	1.1	14
418	Cost-utility analysis of rTMS as add-on therapy to standard care for the treatment of hallucinations in schizophrenia. <i>European Psychiatry</i> , 2022, , 1-32.	0.1	0
419	The Influence of Oxytocin and Prolactin During a First Episode of Psychosis: The Implication of Sex Differences, Clinical Features, and Cognitive Performance. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 666-677.	1.0	6
420	Olanzapine-samidorphane combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?. <i>Expert Review of Neurotherapeutics</i> , 2022, , .	1.4	3
421	Mirtazapine in schizophrenia "an undeservedly overlooked option?. <i>International Clinical Psychopharmacology</i> , 2022, 37, 131-142.	0.9	1



#	ARTICLE	IF	CITATIONS
422	Anti-glutamic acid decarboxylase antibody screening in first-episode psychosis. Australian and New Zealand Journal of Psychiatry, 2023, 57, 603-612.	1.3	1
423	Effect of digital psychoeducation and peer support on the mental health of family carers supporting individuals with psychosis in England (COPE-support): a randomised clinical trial. The Lancet Digital Health, 2022, 4, e320-e329.	5.9	9
424	The correlation between dynamic functional architecture and response to electroconvulsive therapy combined with antipsychotics in schizophrenia. European Journal of Neuroscience, 2022, 55, 2024-2036.	1.2	2
425	Adverse effects of electroconvulsive therapy. The Cochrane Library, 2021, 2021, .	1.5	0
426	Trends in prescription of psychotropic medications to children and adolescents in Australian primary care from 2011 to 2018. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1477-1490.	1.3	17
427	Cognitive strengths in first episode psychosis: a thematic analysis of clinicians' perspectives. BMC Psychiatry, 2021, 21, 612.	1.1	3
428	Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study. World Journal of Biological Psychiatry, 2022, 23, 374-386.	1.3	7
429	Automated Decision Support For Community Mental Health Services Using National Electronic Health Records: Qualitative Implementation Case Study. JMIR Human Factors, 2022, 9, e35403.	1.0	1
430	Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review. International Journal of Neuropsychopharmacology, 2022, 25, 737-758.	1.0	3
431	Cognitive Behavioural Therapy in Children and Adolescents. Research Journal of Pharmacy and Technology, 2022, , 1330-1336.	0.2	3
432	Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 829-846.	1.0	5
434	A 1-Day Training Course to Disseminate the BREF Psychoeducational Program to Caregivers and Promote Network Establishment between Psychiatry Departments and Family Associations. Academic Psychiatry, 2022, , .	0.4	0
439	"You are trying to teach us to think more slowly!"™: Adapting Metacognitive Training for the acute care setting" A case report. Clinical Psychology and Psychotherapy, 2022, 29, 1877-1885.	1.4	4
440	Treatment Effect of Long-Term Antipsychotics on Default-Mode Network Dysfunction in Drug-Naïve Patients With First-Episode Schizophrenia: A Longitudinal Study. Frontiers in Pharmacology, 2022, 13, .	1.6	2
441	Pharmacists in clozapine clinics improving physical health monitoring. Mental Health Clinician, 2022, 12, 193-198.	0.5	3
442	Preparing an integrated self-management support intervention for people living with schizophrenia: Creating collaborative spaces. Journal of Evaluation in Clinical Practice, 2023, 29, 22-31.	0.9	3
443	Efficacy of Integrated Social Cognitive Remediation vs. Neurocognitive Remediation in Improving Functional Outcome in Schizophrenia: Concept and Design of a Multicenter, Single-Blind RCT (The ISST) Tj ETQq0 0.3 rgBT / Overlock 10	0.3	0
444	Feasibility and Effectiveness of a Psychosis-Specific Intensive Outpatient Program. Psychiatric Research and Clinical Practice, 2022, 4, 74-79.	1.3	0

#	ARTICLE	IF	CITATIONS
445	An unusual case of oral surgical management in a patient with isovaleric acidemia and schizophrenia: A case report. <i>Biomedical Reports</i> , 2022, 17, .	0.9	0
446	Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 818-826.	1.0	11
447	Brain stimulation and other biological non-pharmacological interventions in mental disorders: An umbrella review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 139, 104743.	2.9	41
448	Analysis of color vision and cognitive function in first-episode schizophrenia before and after antipsychotic treatment. <i>Journal of Psychiatric Research</i> , 2022, 152, 278-288.	1.5	1
450	Baseline prolactin monitoring in patients admitted to a specialized psychogeriatric unit. <i>Indian Journal of Psychiatry</i> , 2022, 64, 326.	0.4	0
451	Understanding the Treatment Preferences of People Living with Schizophrenia in Australia; A Patient Value Mapping Study. <i>Patient Preference and Adherence</i> , 0, Volume 16, 1687-1701.	0.8	5
452	The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?. <i>International Clinical Psychopharmacology</i> , 2022, 37, 263-275.	0.9	9
453	Management of schizophrenia in women during the perinatal period: a synthesis of international recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1337-1350.	0.9	2
454	Mental health service users' experiences and perspectives of family involvement in their care: a systematic literature review. <i>Journal of Mental Health</i> , 2023, 32, 699-715.	1.0	4
455	A Randomized Control Trial of Cognitive Compensatory Training (CCT) and Computerized Interactive Remediation of Cognition-Training for Schizophrenia (CIRCuiTS). <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
456	Organisational change to integrate self-management into specialised mental health services: Creating collaborative spaces. <i>Journal of Evaluation in Clinical Practice</i> , 0, , .	0.9	1
457	Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211125.	1.2	2
458	Do recovery-oriented messages improve self-efficacy and positive emotions amongst people with lived experience of psychosis? Experimental investigation. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2022, 95, 1003-1017.	1.3	4
459	Neurobiological Perspective and Personalized Treatment in Schizophrenia. , 0, , .		0
460	Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. <i>Molecular Psychiatry</i> , 2023, 28, 354-368.	4.1	27
461	They may be confronting but they are good questions to be asking young people's experiences of completing a trauma and PTSD screening tool in an early psychosis program. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2022, 95, 1090-1107.	1.3	2
462	Dynamics between insight and medication adherence in first-episode psychosis: Study of 3-year trajectories. <i>European Psychiatry</i> , 2022, 65, .	0.1	4
463	Real-world effectiveness of mood stabilizer use in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2023, 147, 257-266.	2.2	7

#	ARTICLE	IF	CITATIONS
464	Neuroimaging in the Acute Psychiatric Setting: Associations With Neuropsychiatric Risk Factors. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2023, 35, 184-191.	0.9	0
465	A WeChat-based self-compassion training to improve the treatment adherence of patients with schizophrenia in China: Protocol for a randomized controlled trial. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	0
466	Underuse of recommended treatments among people living with treatment-resistant psychosis. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	3
467	Anti-N-Methyl-Aspartate Receptor Antibody Testing in First-Episode Psychosis: Universal or Targeted Testing. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2023, 35, 98-101.	0.9	0
468	Barriers and facilitators when implementing family involvement for persons with psychotic disorders in community mental health centres – a nested qualitative study. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	9
469	Recruitment, attrition and intervention completion in clinical trials of psychosocial interventions involving people with early and emerging psychosis: a systematic review protocol. <i>BMJ Open</i> , 2022, 12, e060863.	0.8	0
470	Clozapine shared care: mental health services and GPs working together for better outcomes for people with schizophrenia. <i>Medical Journal of Australia</i> , 2022, 217, .	0.8	2
471	Shared guidelines and protocols to achieve better health outcomes for people living with serious mental illness. <i>Medical Journal of Australia</i> , 2022, 217, .	0.8	2
472	Pathophysiology, prognosis and treatment of tardive dyskinesia. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211173.	1.2	8
473	Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	1
474	A training programme for community pharmacists to support people living with severe and persistent mental illness: Intervention mapping in the context of a pandemic. <i>Health Education Journal</i> , 2022, 81, 964-981.	0.6	9
475	Olanzapine/samidorphane combination consistently mitigates weight gain across various subgroups of patients. <i>CNS Spectrums</i> , 0, , 1-4.	0.7	2
476	Neuropsychopharmacotherapy: Guidelines. , 2022, , 823-853.		0
477	Neuropsychopharmacotherapy in Children and Adolescents. , 2022, , 4383-4398.		0
478	Psychotropic medicines are frequently dosed outside recommended ranges: a clinical audit in an Australian mental health hospital. <i>Journal of Pharmacy Practice and Research</i> , 0, , .	0.5	0
479	Clozapine Blood Concentration Predicts Corrected QT-Interval Prolongation in Patients With Psychoses. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 536-543.	0.7	7
480	Psychotropic medication use in people living with severe and persistent mental illness in the Australian community: a cross-sectional study. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	6
481	Clozapine haematological monitoring for neutropenia: a global perspective. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, .	1.8	21

#	ARTICLE	IF	CITATIONS
482	Syndrome of subjective doubles as a rare presentation of a first-episode psychosis. <i>BMJ Case Reports</i> , 2022, 15, e249356.	0.2	0
483	Schizophrenie. <i>Psychotherapie: Manuale</i> , 2023, , 9-57.	0.0	0
484	Physical Health and Activity of Inpatients under Forensic Mental Health Care: A Cross-Sectional Survey and Audit of Patients in a High Secure Setting in Queensland, Australia. <i>International Journal of Forensic Mental Health</i> , 2024, 23, 12-23.	0.6	0
485	The duty of confidentiality during family involvement: ethical challenges and possible solutions in the treatment of persons with psychotic disorders. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	3
486	Patients' and primary carers' views on clozapine treatment for schizophrenia: A cross-sectional study in Qatar. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 214-221.	1.2	4
487	Getting the FACS: A Protocol for Developing a Survey Instrument to Measure Carer and Family Engagement with Mental Health Services. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16279.	1.2	0
488	Patients with severe mental illness and the ethical challenges related to confidentiality during family involvement: A scoping review. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
489	Physical Healthcare for People with a Severe Mental Illness in Belgium by Long-Term Community Mental Health Outreach Teams: A Qualitative Descriptive Study on Physiciansâ€™, Community Mental Health Workersâ€™ and Patientsâ€™ Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 811.	1.2	2
491	Behavioural activation for depressive symptoms in young people with emerging or early psychosis: A pilot study protocol. <i>PLoS ONE</i> , 2023, 18, e0280559.	1.1	1
492	The Lived Experiences of Family Members and Carers of People with Psychosis: A Bottom-Up Review Co-Written by Experts by Experience and Academics. <i>Psychopathology</i> , 2023, 56, 371-382.	1.1	5
493	Ultra-Treatmentâ€™Resistant Schizophrenia and Clozapine Augmentation. <i>Journal of Clinical Psychopharmacology</i> , 2023, 43, 183-184.	0.7	0
494	Is there Any Relevance for the Use of Cyamemazine in the Treatment of Schizophrenia?. <i>Indian Journal of Private Psychiatry</i> , 2023, 17, 14-19.	0.1	0
495	Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States. <i>Journal of Medical Economics</i> , 2023, 26, 525-536.	1.0	1
497	Participantsâ€™ Evaluation and Outcomes following Integration of Self-Management Support into Outpatient Schizophrenia Case Management. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3035.	1.2	2
499	Implementation of Guidelines on Family Involvement for Persons with Psychotic Disorders (IFIP): A Cluster Randomised Controlled Trial. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2023, 50, 520-533.	1.2	3
500	Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review. <i>Genes</i> , 2023, 14, 689.	1.0	2
501	Effectiveness of Clozapine on Employment Outcomes in Treatment-Resistant Schizophrenia: A Retrospective Bidirectional Mirror-Image Study. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 19, 615-622.	1.0	0
502	Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 473-493.	0.9	6

#	ARTICLE	IF	CITATIONS
503	Sudden Cardiac Death in People With Schizophrenia. <i>JACC: Clinical Electrophysiology</i> , 2023, , .	1.3	1
505	The use of implementation science to close the research-to-treatment gap for cognitive impairment in psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 1308-1315.	1.3	2
506	Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2023, 13, 204512532311581.	1.2	3
507	The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	5
508	Development of an Interprofessional Psychosocial Interventions Framework. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5495.	1.2	1
509	Approach to schizophrenia. <i>Internal Medicine Journal</i> , 2023, 53, 473-480.	0.5	2
510	Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2023, 43, 246-258.	0.7	2
511	Currently available means to achieve personalized psychiatry. <i>Personalized Medicine in Psychiatry</i> , 2023, 39-40, 100105.	0.1	0
535	Neurodevelopmental disorders. , 2023, , .		0
536	Psychosocial Interventions to Support Community Living: Rehabilitation, Recovery, and Rights. , 2023, , 1-48.		0
549	Biomarkers of Schizophrenia. , 2023, , 207-218.		0
552	Delivery of Neuropsychological Interventions for Adult and Older Adult Clinical Populations: An Australian Expert Working Group Clinical Guidance Paper. <i>Neuropsychology Review</i> , 0, , .	2.5	0
557	Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review. <i>CNS Drugs</i> , 2024, 38, 105-123.	2.7	0
570	First Episode of Psychosis. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2024, , 65-87.	0.3	0